• Slovenščina
  • English
  • Hrvatski

+386 1 438 16 00

  

info@rapharm.eu

raPHARM raPHARM
  • Who we are
  • What we do
    • Consulting & Services
    • Regulatory intelligence
    • Education & Training
    • International projects
  • Actual educations
  • News
  • Application form
    • Apply for consultation
    • Apply for education
  • Contact

Category: <span>Uncategorized</span>

Home / Uncategorized

EU: Two new guidelines have been published and approved by the MDCG

0
On 27/10/202227/10/2022By rapharmIn Novice, Uncategorized

On 14 September, two new guidelines, MDCG 2022-15 and MDCG 2021-22, were published on the website of the European Commission...

Read More

EU: On 4 July 2022, the European Commission accepted Implementing Regulation 2022/1107 laying down common specifications for certain class D in vitro diagnostic medical devices (IVDs) in accordance with Regulation (EU) 2017/746

0
On 08/07/202211/07/2022By rapharmIn Novice, Uncategorized

In the document European Commission explains that for certain class D IVDs harmonised standards do not exist and since the...

Read More

EU: MDCG Position paper has been published

0
On 21/06/202221/06/2022By rapharmIn Novice, Uncategorized

In June, a Position paper MDCG 2022-11 was published on the website of the European Commission and approved by the...

Read More

EU: New guideline has been published and approved by the MDCG

0
On 17/06/202217/06/2022By rapharmIn Novice, Uncategorized

In May, a new guideline, MDCG 2022-8 was published on the website of the European Commission and approved by the...

Read More

EU: Evaluation of cannabidiol (CBD) as a novel food suspended

0
On 15/06/202215/06/2022By rapharmIn Novice, Uncategorized

The European Food Safety Authority (EFSA) currently suspending the evaluation of CBD as a novel food, as current scientific documentation...

Read More

EU: New guideline has been published and approved by the MDCG

0
On 07/06/202208/06/2022By rapharmIn Novice, Uncategorized

In May, a new guideline, MDCG 2022-8 was published on the website of the European Commission and approved by the...

Read More

EU: Status of the EU-Switzerland Mutual Recognition Agreement (MRA) for in vitro diagnostic medical devices

0
On 06/06/202206/06/2022By rapharmIn Novice, Uncategorized

Switzerland participates in the internal market of the European Union through the Agreement on Mutual Recognition in relation to conformity...

Read More

EU: New harmonized standards for MDR and IVDR regulation have been published

0
On 27/05/202227/05/2022By rapharmIn Novice, Uncategorized

In May 2022, Commission Implementing Decisions (EU) 2022/757 on new harmonized standards for MDR and 2022/729 on new harmonized standards...

Read More

EU: Two new guidelines have been published and approved by the MDCG

0
On 12/05/202216/05/2022By rapharmIn Novice, Uncategorized

Recently, two new guidelines, MDCG 2022-5 and MDCG 2022-6, were published on the website of the European Commission and approved...

Read more

EU: European Commission begins intensive work on maximum daily levels of vitamins and minerals in food supplements

0
On 03/05/202203/05/2022By rapharmIn Novice, Uncategorized

Two decades after the adoption of Directive 2002/46 / EC of the European Parliament and of the Council of 10...

Read More
  • 1
  • 2
  • 3

About raPHARM

raPHARM is a consultancy and education office specialising in pharmaceutical and medical devices regulatory affairs. The office was founded by Ms Vesna Koblar, MD. PhD., an internationally recognised expert in this area with extensive experience and knowledge.

Navigation

  • Who we are
  • What we do
  • Actual educations
  • News
  • Application form
  • Contact

Application form

  • Apply for consultation
  • Apply for education

Contact

  • raPHARM, Ltd.
  • 30 Miklošičeva Street
  • SI-1000 Ljubljana, Slovenia, EU
  • E: info@rapharm.eu
  • T: +386 1 438 16 00
© 2025 raPHARM d.o.o.
raPharm.eu website uses cookies for operational purposes and web analytics.